Pharmacogenetics of Efavirenz Discontinuation for Reported CNS Symptoms

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.

H. Ribaudo, Huan Liu, M. Schwab, et al.. (2010). The Journal of infectious diseases. Cited 147 times. https://doi.org/10.1086/655470

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

E. Holzinger, Benjamin J. Grady, M. Ritchie, et al.. (2012). Pharmacogenetics and Genomics. Cited 140 times. https://doi.org/10.1097/FPC.0b013e32835a450b

Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.

R. Lubomirov, S. Colombo, J. di Iulio, et al.. (2011). The Journal of infectious diseases. Cited 108 times. https://doi.org/10.1093/infdis/jiq043

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

D. Haas, A. Kwara, Danielle M Richardson, et al.. (2014). The Journal of antimicrobial chemotherapy. Cited 52 times. https://doi.org/10.1093/jac/dku110

Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race

P. Leger, S. Chirwa, M. Turner, et al.. (2016). Pharmacogenetics and Genomics. Cited 24 times. https://doi.org/10.1097/FPC.0000000000000238